ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Sees Large Decline in Short Interest

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 2,050,000 shares, a drop of 9.7% from the September 30th total of 2,270,000 shares. Based on an average daily volume of 352,600 shares, the days-to-cover ratio is currently 5.8 days.

Analyst Ratings Changes

A number of brokerages recently issued reports on ANIP. HC Wainwright reissued a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Raymond James raised their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. Finally, Truist Financial raised their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $77.33.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $57.25 on Friday. ANI Pharmaceuticals has a 1 year low of $48.20 and a 1 year high of $70.81. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of 48.93 and a beta of 0.71. The business has a 50-day moving average of $59.27 and a 200-day moving average of $61.88.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.07. The firm had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The business’s revenue was up 18.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.06 earnings per share. As a group, equities research analysts anticipate that ANI Pharmaceuticals will post 3.51 earnings per share for the current year.

Institutional Trading of ANI Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Innealta Capital LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter valued at $65,000. Ridgewood Investments LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter worth about $85,000. SG Americas Securities LLC bought a new position in ANI Pharmaceuticals in the 1st quarter worth about $106,000. XTX Topco Ltd bought a new position in ANI Pharmaceuticals in the 2nd quarter worth about $207,000. Finally, O Shaughnessy Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter worth about $218,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.